Among adults with type 2 diabetes (T2D) initiating second-line antidiabetic medication (ADM) therapy, the short-term cardiovascular (CV) outcomes of glucagon-like peptide-1 (GLP-1) receptor agonists, sodium-glucose cotransporter 2 (SGLT-2) inhibitors, and dipeptidyl peptidase 4 (DPP-4) inhibitors were similar, a recent study found. The cohort study included 132,737 adults (aged 45-64 years) with T2D and examined the association of second-line ADM classes with major adverse CV events. Researchers found:
- GLP-1 receptor agonists, DPP-4 inhibitors, and SGLT-2 inhibitors were associated with similar CV outcomes.
- Sulfonylureas and basal insulin were associated with comparatively higher CV risk.
- Clinicians may consider prescribing newer ADM classes more routinely after metformin.
O’Brien MJ, Karam SL, Wallia A, et al. Association of second-line antidiabetic medications with cardiovascular events among insured adults with type 2 diabetes. JAMA Netw Open. 2018;1(8):e186125. doi:10.1001/jamanetworkopen.2018.6125.
This Week's Must Reads
Do Vitamin D Supplements Prevent Cancer, CVD?, N Engl J Med; 2019 Jan 3; Manson, Cook, et al
Nonadherence to Cancer Screenings & Related Mortality, JAMA Intern Med; ePub 2018 Dec 28; Pierre-Victor, et al
Alcohol Consumption After Development of HF, JAMA Netw Open; ePub 2018 Dec 28; Sadhu, et al
Opioid-Involved Overdose Deaths in the US, MMWR; 2019 Jan 4; Scholl, Seth, et al
Assessing the Diet Quality of US Children, Am J Clin Nutrit; ePub 2018 Dec 29; Thomson, et al
Must Reads in Diabetes
Second-Line ADMs & CV Events in T2D, JAMA Netw Open; ePub 2018 Dec 21; O’Brien, et al
Rotating Night Shift Work & Risk of T2D, BMJ; ePub 2018 Nov 21; Shan, Li, et al
BMI & Risk of Postpregnancy T2D in Women with HDP , Diabetes Care; ePub 2018 Nov 19; Timpka, et al
Diabetes Outcomes in Patients by PCPs, NPs, or PAs, Ann Intern Med; ePub 2018 Nov 20; Jackson, et al
Diabetes-Related Lower Extremity Amputations, Diabetes Care; ePub 2018 Nov 8; Geiss, et al